Trials / Completed
CompletedNCT02332473
A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B
A Prospective Phase 2 Clinical Trial to Assess the Efficacy and Safety of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis Patients.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center, randomized, prospective open-label study to assess the efficacy and safety of combination of peginterferon alfa-2b (40kD, Y-shape) and GM-CSF in interferon-naïve chronic hepatitis B patients with HBeAg positive. Patients were randomized to one of the 2 groups to receive different antiviral treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ypeginterferon alfa-2b | |
| DRUG | Granulocyte-macrophage colony stimulating factor |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2016-02-01
- Completion
- 2016-08-01
- First posted
- 2015-01-06
- Last updated
- 2017-01-25
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02332473. Inclusion in this directory is not an endorsement.